Evotec SE (EVO)
NASDAQ: EVO · Real-Time Price · USD
3.030
+0.040 (1.34%)
May 22, 2026, 4:00 PM EDT - Market closed
Evotec SE Revenue
Evotec SE had revenue of 156.64M EUR in the quarter ending March 31, 2026, a decrease of -21.67%. This brings the company's revenue in the last twelve months to 745.04M, down -5.48% year-over-year. In the year 2025, Evotec SE had annual revenue of 788.37M, down -1.08%.
Revenue (ttm)
745.04M EUR
Revenue Growth
-5.48%
P/S Ratio
1.21
Revenue / Employee
164,613 EUR
Employees
4,526
Market Cap
1.04B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 788.37M | -8.59M | -1.08% |
| Dec 31, 2024 | 796.97M | 15.54M | 1.99% |
| Dec 31, 2023 | 781.43M | 29.98M | 3.99% |
| Dec 31, 2022 | 751.45M | 133.41M | 21.59% |
| Dec 31, 2021 | 618.03M | 117.11M | 23.38% |
| Dec 31, 2020 | 500.92M | 54.49M | 12.20% |
| Dec 31, 2019 | 446.44M | 71.03M | 18.92% |
| Dec 31, 2018 | 375.41M | 111.64M | 42.33% |
| Dec 31, 2017 | 263.77M | 99.26M | 60.34% |
| Dec 31, 2016 | 164.51M | 36.83M | 28.85% |
| Dec 31, 2015 | 127.68M | 38.18M | 42.66% |
| Dec 31, 2014 | 89.50M | 3.56M | 4.14% |
| Dec 31, 2013 | 85.94M | -1.33M | -1.52% |
| Dec 31, 2012 | 87.27M | 7.14M | 8.91% |
| Dec 31, 2011 | 80.13M | 24.87M | 45.00% |
| Dec 31, 2010 | 55.26M | 12.58M | 29.47% |
| Dec 31, 2009 | 42.68M | 3.07M | 7.75% |
| Dec 31, 2008 | 39.61M | -14.77M | -27.16% |
| Dec 31, 2007 | 54.38M | -30.30M | -35.78% |
| Dec 31, 2006 | 84.68M | 4.90M | 6.14% |
| Dec 31, 2005 | 79.79M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Phibro Animal Health | 1.50B |
| Collegium Pharmaceutical | 796.33M |
| Pacira BioSciences | 734.86M |
| Amphastar Pharmaceuticals | 720.53M |
| Alvotech | 562.04M |
| Esperion Therapeutics | 418.24M |
| Xeris Biopharma Holdings | 314.85M |
| Harrow | 268.68M |
EVO News
- 3 days ago - EQS-DD: Evotec SE: Dr. Cord Dohrmann, sell - Wallstreet:Online
- 12 days ago - Evotec SE (EVO) Issues â¬116.1M Convertible Bonds to Support Project Horizon - GuruFocus
- 13 days ago - Evotec SE Successfully Placed €116.1 Million Convertible Bonds - Accesswire
- 13 days ago - EQS-Adhoc: Evotec SE launches approximately EUR 125 million convertible bond offering - Wallstreet:Online
- 20 days ago - EQS-DD: Evotec SE: Paul Hitchin, Restricted shares granted as Short Term Variable Incentive (Bonus) for 2025 pursuant Evotec’s remuneration system. - Wallstreet:Online
- 20 days ago - EQS-DD: Evotec SE: Aurélie Dalbiez, Restricted shares granted as Short Term Variable Incentive (Bonus) for 2025 pursuant Evotec’s remuneration system. - Wallstreet:Online
- 20 days ago - EQS-DD: Evotec SE: Dr. Christian Wojczewski, Restricted shares granted as Short Term Variable Incentive (Bonus) for 2025 pursuant Evotec’s remuneration system. - Wallstreet:Online
- 20 days ago - EQS-DD: Evotec SE: Dr. Cord Dohrmann, Restricted shares granted as Short Term Variable Incentive (Bonus) for 2025 pursuant Evotec’s remuneration system. - Wallstreet:Online